Concord Medical Services Holdings Limited (NYSE:CCM) Short Interest Update

Posted by Renee Jackson on Aug 31st, 2026

Concord Medical Services Holdings Limited (NYSE:CCM – Get Free Report) saw a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 7,578 shares, an increase of 63.3% from the July 30th total of 4,641 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average trading volume of 117,289 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

CCM has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Concord Medical Services to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Concord Medical Services in a report on Friday, August 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Get Our Latest Report on CCM

Concord Medical Services Stock Performance

Shares of Concord Medical Services stock traded down $0.20 on Monday, hitting $4.56. The company had a trading volume of 25,670 shares, compared to its average volume of 40,232. The stock has a 50-day moving average of $4.64 and a 200-day moving average of $4.34. The company has a quick ratio of 0.46, a current ratio of 0.48 and a debt-to-equity ratio of 1.33. Concord Medical Services has a twelve month low of $3.18 and a twelve month high of $6.98.

About Concord Medical Services

(Get Free Report)

Concord Medical Services Holdings Limited is one of China’s leading providers of radiotherapy equipment and oncology services. The company specializes in supplying and operating advanced radiotherapy machines, including linear accelerators, computed tomography (CT) simulators and brachytherapy units, to public and private hospitals. Through its integrated service model, Concord Medical Services delivers treatment planning, machine maintenance and clinical support to enhance the precision and effectiveness of cancer therapies.

Founded in 1997 and headquartered in Beijing, Concord Medical Services has developed an extensive network of oncology centers across major cities and provinces in China.